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Abstract: The relationship between body weight and different cancers is now well-recognized and 
among such cancers, colorectal cancer (CRC) is reported most frequently. Our group recently 
published findings, through an epigenome-wide association study, suggesting that body mass 
index (BMI) could act as a relevant risk factor in the CRC. In addition, aberrant SFRP2 methylation 
is one of the major mechanisms for Wnt signaling activation in CRC. Conversely, 
neoadjuvant chemo-radiotherapy appears to alter the rectal cancer epigenome. This study was 
aimed to evaluate the effect of obesity, measured by BMI, on the methylation of SFRP2 in tumor 
samples of patients with CRC. Non-treated CRC patients and CRC patients treated with 
pre-operative neoadjuvant therapy from 2011 to 2013 were included and classified by BMI < 25.0 
kg/m2 and BMI > 25.0 kg/m2. SFRP2 DNA methylation in tumor samples was measured by 
pyrosequencing. Our findings suggest a possible interaction between SFRP2 methylation levels 
and BMI in CRC tumor samples. The correlation of SFRP2 hypomethylation with an elevated BMI 
was stronger within the non-treated CRC patient group than within the treated CRC patient group. 
We have successfully demonstrated that the beneficial association of tumor SFRP2 
hypomethylation is dependent on patient BMI in non-treated CRC, suggesting a possible tumor 
suppressor role for SFRP2 in overweight and obese patients. Additional studies of clinical 
pathologies would be necessary to strengthen these preliminary results. 
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Abstract: The relationship between body weight and different cancers is now well-recognized and
among such cancers, colorectal cancer (CRC) is reported most frequently. Our group recently published
findings, through an epigenome-wide association study, suggesting that body mass index (BMI) could
act as a relevant risk factor in the CRC. In addition, aberrant SFRP2 methylation is one of the major
mechanisms for Wnt signaling activation in CRC. Conversely, neoadjuvant chemo-radiotherapy
appears to alter the rectal cancer epigenome. This study was aimed to evaluate the effect of obesity,
measured by BMI, on the methylation of SFRP2 in tumor samples of patients with CRC. Non-treated
CRC patients and CRC patients treated with pre-operative neoadjuvant therapy from 2011 to 2013
were included and classified by BMI < 25.0 kg/m2 and BMI > 25.0 kg/m2. SFRP2 DNA methylation
in tumor samples was measured by pyrosequencing. Our findings suggest a possible interaction
between SFRP2 methylation levels and BMI in CRC tumor samples. The correlation of SFRP2
hypomethylation with an elevated BMI was stronger within the non-treated CRC patient group
than within the treated CRC patient group. We have successfully demonstrated that the beneficial
association of tumor SFRP2 hypomethylation is dependent on patient BMI in non-treated CRC,
suggesting a possible tumor suppressor role for SFRP2 in overweight and obese patients. Additional
studies of clinical pathologies would be necessary to strengthen these preliminary results.
Keywords: SRFP2; DNA methylation; BMI; colorectal cancer; therapy; location
1. Introduction
One of the biggest challenges facing biomedical science is finding promising diagnostic, prognostic,
and predictive biomarkers of non-communicable diseases of multi-factorial origin, such as colorectal
J. Clin. Med. 2019, 8, 1041; doi:10.3390/jcm8071041 www.mdpi.com/journal/jcm
J. Clin. Med. 2019, 8, 1041 2 of 12
cancer (CRC). Based on global cancer statistics, CRC is one of the leading causes of mortality from
all cancers and the cancer-related mortality has increased by almost 40% in the last 40 years [1].
Consequently, novel promising biomarkers are required to increase the CRC screening sensitivity and
predict more effective responses to individual cancer therapies.
DNA and miRNAs methylation of tumor suppressor genes and oncogenes is a key process in
human carcinogenesis [2,3]. Moreover, epigenetic changes of tumor suppressor genes are a recognized
factor in Knudson´s model of cancer [4]. According to the literature, epigenetic remodeling of
several genes (KRAS, APC, p53, DCC, genes of the Rho family of GTPases, MACC1, Met, MTA1,
RASSF1A, SFRP1, etc.) are associated with malignant cellular transformation, progression, invasion,
and metastasis in colorectal cancers [5–7]. Consequently, aberrant DNA methylation also offers an
opportunity for its exploitation as ideal biomarkers for CRC prediction, diagnosis, and prognosis [8].
Furthermore, the identification and validation of several hyper- and hypomethylated genes in CRC
can be highly useful for employment as novel biomarkers for tumor development. Previous studies in
CRC observed that LINE-1 (long interspersed nucleotide element) hypomethylation was associated
with more advanced disease stages [9,10].
One important example of such key molecular players is the secreted frizzled-related protein type 2
(SFRP2), which can be deemed as a potential epigenetic biomarker of CRC. Moreover, SFRP2 (a Wnt
signaling inhibitor) is hypermethylated in CRC [11–13]. Recently, a number of studies demonstrated
that SFRP2 is not only hypermethylated in CRC tissue, but also in a spectrum of biological tissues
including blood and stools, suggesting that SFRP2 methylation might be a potential non-invasive
biomarker for CRC screening [14–16].
Currently, it is well established that excess body weight, defined by the body mass index (BMI),
can be considered to be a risk factor for the incidence and progression of CRC [17]. The underlying
mechanisms linking obesity to CRC are still a matter of debate. However, BMI-associated DNA
methylation profile changes could provide one of the missing links between obesity and CRC [18].
Recently, we have reported that the hyper-methylation of the SFRP2 promoter exhibited a strong
correlation with BMI in tumor samples, consequently suggesting adiposity as a prognostic factor in
patients with CRC [14].
Presently, neoadjuvant chemo-radiotherapy, followed by radical surgery is considered to be
the standard of care for patients with locally advanced rectal cancer [19]. Several authors have
described how the patient characteristics, such as BMI and internal distribution of adipose tissue,
have the potential to interfere with radiation dosing or delivery, leading to appreciable differences
in treatment response and survival outcomes [20]. On the other hand, some studies have reported
that DNA methylation could be a crucial factor that determines oncological treatment efficacy of, both,
chemotherapy and radiotherapy [21]. However, it has been suggested that oncological treatment
can also induce epigenetic changes that could mediate treatment response [22]. Ultimately, novel
therapeutic approaches opt for utilizing adjuvant methyltransferase inhibitors, in order to increase
treatment efficacy [23].
Considering the correlation between the SFRP2 methylation status and BMI in CRC patients [14],
together with the potential effect of neoadjuvant treatment on DNA methylation pattern; we propose that
SFRP2 methylation could be associated with specific clinical outcome of CRC patients and this relationship
could be affected by BMI or treatment. In the present study, we have specifically focused on the analysis
of tumor and non-tumor samples for the methylation status of SFRP2 in an independent prospective
cohort study, together with its association with the clinical and pathological features of CRC patients.
2. Materials and Methods
2.1. Study Population
A total of 75 CRC patients diagnosed by biopsy or colonoscopy were included in the present
study from Virgen de la Victoria University Hospital (Málaga, Spain), recruited from October 2011 to
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September 2013. One cohort group consisted of 53 overweight or obese patients (BMI > 25 kg/m2),
while 22 were non-obese participants (BMI < 25 kg/m2). All participants underwent surgery with
curative intention, by hemicolectomy, lower anterior resection with ileostomy (caused by a carcinoma
of the CRC), followed by a total mesocolorectal excision. A formalin-fixed paraffin-embedded (FFPE)
(10 sections of 14 µm) tumor area and an adjacent tumor-free area were obtained from all CRC patients.
Participants included in the study had primary CRC whose medical records/pathological
examinations were complete. The exclusion criteria were patients with inflammatory bowel disease
(Crohn´s disease or ulcerative colitis) and patients who had evidence of hereditary non-polyposis
colorectal cancer or familial adenomatous polyposis. All participants were anonymized and gave their
written informed consent. The study was performed in accordance with the Declaration of Helsinki
and was approved by the Ethics Committees of Virgen de la Victoria University Hospital (registration
number 0311/PI7) (Málaga, Spain).
The clinical–pathological parameters of the cohort groups were confirmed by reviewing the patient
medical records and pathology files. The pathological diagnosis, tumor histology, and staging were
performed according to the Classification of the “World Health Organization Classification of Tumours
of the Digestive System” (2016) [24]. Rectal cancer patients were treated according to local protocols,
after a routine workout, including a turaco abdominal scan and a pelvis MRI. Those classified as T3–4
or N 1–3 were proposed for neoadjuvant chemoradiation treatment with pelvic radiotherapy 50Gy
(2 Gy/fraction) and concomitant administration of fluoropyrimidine-based chemotherapy, followed
by total mesorectal excision in 6–8 weeks. Patients were sub-classified as treated (those that were
designated for neoadjuvant therapy), while those who did not receive any pre-operative treatment
were classified as non-treated.
2.2. Biochemical Determination
Fasting blood samples were obtained from the antecubital vein and placed in vacutainer tubes
(BD Vacutainer™, Franklin Lakes, NJ, USA). Serum glucose, total cholesterol, triglycerides, and HDL
cholesterol (HDL-c) were measured in a Dimension auto analyzer (Dade Behring Inc., Deerfield, IL, USA)
through enzymatic methods (Randox Laboratories Ltd., Crumlin, UK). The LDL cholesterol (LDL-c)
was calculated using the Friedewald equation [25]. Insulin was quantified by radioimmunoassay
(BioSource International, Camarillo, CA, USA). Corrected calcium was assessed using a complex metric
method from Boehringer Hitachi 717. Alkaline phosphatase was calculated using ELISA (LifeSpan
Biosciences Inc., Madrid, Spain). Insulin growth factor type 1 (IGF-1) was determined using Human
IGF1 ELISA Kit (Abcam, Madrid, Spain). The homeostasis model assessment of insulin resistance
(HOMA-IR) was calculated using the following equation: HOMA-IR = fasting insulin (IU/mL) x fasting
glucose (mmol/L)/22.5 [26].
2.3. Human Colorectal CarcinomaCell Lines and SFRP2 Expression Assay by RT-qPCR
HTC116 cell line (Homo Sapiens colon colorectal carcinoma, ATCC, Manassas, VA, USA), LoVo
cell line (Homo Sapiens colorectal adenocarcinoma derived from metastatic site—left supraclavicular
region, ATCC, Manassas, VA, USA) and Caco-2 cell line (Homo Sapiens colon colorectal adenocarcinoma,
ATCC, Manassas, VA, USA) were used to study the gene expression of SFRP2. Cells were cultured in
Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum, penicillin, and streptomycin
at 37 ◦C and 5% CO2. Cell lines were treated with the DNA demethylation agent 5-aza-2′-deoxycitydine
(AZA) (A3656, Sigma Aldrich, Madrid, Spain) at 5µM for 72 hours.
Consequently, RNA from cell lines was isolated using QiampRNA Mini Kit (Qiagen GmbH,
Hilden, Germany), according to the manufacturer’s instructions. The purity and concentration of the
RNA was determined by the 260/280 absorbance ratio using the Nanodrop 2000 platform (Thermo
scientific, USA). For cDNA synthesis, a fixed amount of 1 µg of the total RNA was reverse transcribed
using random hexamers as primers and Moloney Murine Leukemia Virus reverse transcriptase (Roche
Diagnostic, Rotkreuz, Switzerland). Gene expression was assessed by real-time PCR, using an Applied
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Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems, Darmstadt, Germany) with TaqMan
technology. The reaction was performed following the manufacturer's protocol of TaqMan technologies
Premix Ex Taq™ (Probe qPCR) (Takara, Madrid, Spain), in a final volume of 12.5 µL. The cycle program
consisted of an initial denaturing of 20 s at 95 ◦C, then 45 cycles of a 3 s denaturing phase at 95 ◦C,
followed by a 30 s annealing period. The commercially available and revalidated TaqMan primer/probe
sets used in our samples were SFRP2 and PPIA TaqMan Probes (IDT technologies, Madrid, Spain).
A threshold cycle (Ct value) was obtained for each amplification curve and a ∆Ct value was first
calculated by subtracting the Ct value for Cyclophilin A cDNA from the Ct value for each sample and
transcript. Fold changes compared with the endogenous control were then determined by calculating
2−∆Ct, and relative quantification results were obtained.
2.4. DNA Extraction, Bisulfite Treatment, and Pyrosequencing
Total genomic DNA from 75 CRC paraffin samples (formalin-fixed paraffin embedded (FFPE)
(10 sections of 14 µm) was isolated using the QIAmp DNA FFPE Tissue Kit (Qiagen GmbH, Hilden,
Germany), with a xylene wash, to remove the paraffin. DNA concentration and quality was determined
using NanoDrop 2000 (Thermo scientific, USA). DNA methylation analyses were performed using
bisulfite-treated DNA, followed by a highly quantitative analysis, based on PCR-based pyrosequencing.
The bisulfite conversion was conducted with 2 µg of genomic DNA isolated from each sample, using
Epitect Bisulfite conversion, according to the manufacturer´s instructions (Qiagen GmbH, Hilden,
Germany). Consequently, the SFRP2 promoter and LINE-1 amplification steps were performed in a
total volume of 25 µL, with a starting primer concentration of 10 µM (SFRP2: Primer 5′3′ forward and
reverse respectively: TTTGATTTTTTTAYGGTATTGGGGAGTA and ATAAAACCCRAAACCTACCC.
LINE-1: Primer 5′3′ forward and reverse respectively: TAGGGAGTGTTAGATAGTGG and
AACTCCCTAACCCCTTAC). The reverse primer was biotinylated, in order to purify the final
PCR product, using sepharose beads. Finally, 20 µL of the PCR products were pyro sequenced using
the PyroMarkTMQ96 ID Pyrosequencing System, using a 0.4 µM sequencing primer. The primer
sequences used in this analysis were designed using Qiagen’s PyroMark Assay Design 2.0 software
(Qiagen, Hilden, Germany).
The methylation level was expressed as the percentage of methylated cytosine over the sum of
methylated and unmethylated cytosines. Non-CpG cytosine residues were used as built-in controls to
verify bisulfite conversion. The values are expressed as the mean for all the sites and individually for
seven CpGs at the SFRP2 gene promoter and for six CpGs at the LINE-1 sequence [27,28]. We also
included unmethylated and methylated DNA as controls in each run (New England Biolabs, Ipswich,
MA, USA).
2.5. Statistical Analysis
The results were expressed as the mean ± standard deviation (or percentage) where appropriate.
Student’s t test was used for comparing anthropometric and biochemical data between non-obese
and overweight/obese groups. Paired t-test was performed to compare means between tumor and
tumor-free area. Student’s t test and Mann–Whitney U-test were used for comparisons of LINE-1
and SFRP2 methylation between study groups. Spearman’s correlation analyses were performed to
study the correlations between LINE-1 and SFRP2 methylation. A regression linear model was used to
perform multivariate analysis. All analyses were performed using the R statistical software, version
2.8.1 (Department of Statistics, University of Auckland, Auckland, NZ; http://www.rproject.org/).
3. Results
3.1. Clinical, Anthropometrical, and Biochemical Characteristics of the CRC Patients
There were no differences in anthropometric and biochemical variables between subjects with
BMI < 25 or BMI > 25, except for the BMI itself (as expected) and the insulin levels (Table 1).
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Table 1. Baseline clinical, anthropometrical, and biochemical variables of the colorectal cancer (CRC)
patients, according to the body mass index (BMI). Data are expressed as mean ± standard deviations
or proportions.
Variables BMI < 25 kg/m
2
(n = 22)
BMI > 25 kg/m2
(n = 53)
p-Value
Age (years) 62.91 ± 11.21 66.64 ± 7.91 NS
Male/female 14/8 38/15 NS
BMI (kg/m2) 23.33 ± 1.32 29.20 ± 3.43 p < 0.05
Waist circumference (cm) 89.80 ± 12.01 101.39 ± 12.93 NS
Glucose (mg/dL) 122.57 ± 48.51 120.00 ± 40.40 NS
Insulin (µUI/mL) 4.07 ± 2.30 7.16 ± 5.63 p < 0.05
HOMA-IR 1.42 ± 1.38 2.25 ± 2.17 NS
Diabetes Mellitus (%) 30 29.2 NS
Triglycerides (mg/dL) 146.71 ± 76.36 171.92 ± 82.52 NS
Total cholesterol (mg/dL) 180.76 ± 39.90 169.13 ± 36.60 NS
HDL-c (mg/dL) 42.86 ± 15.07 39.51 ± 13.57 NS
LDL-c (mg/dL) 109.99 ± 30.94 100.72 ± 30.88 NS
Corrected calcium (mg/dL) 9.09±0.32 8.94 ± 0.54 NS
Alkaline phosphatase (U/L) 63.09 ± 26.76 72.57 ± 30.65 NS
IGF-1 (ng/mL) 137.26 ± 48.41 128.75 ± 73.92 NS
Abbreviations: BMI—Body mass index; NS—Non-significant; HOMA-IR—Homeostasis model assessment of
insulin resistance; HDL-c—High density lipoprotein cholesterol; LDL-c—Low density lipoprotein cholesterol;
IGF-1—Insulin growth factor type 1.
3.2. Methylation Status of SFRP2 in CRC Tissue
First of all, we initiated our analysis based on previous data of the SFRP2 promoter performed
and published by our group and obtained from the Infinium Human Methylation 450 BeadChip
array [14].The study sequence of the SFRP2 promoter used in our analysis showed seven CpG sites
in the position −1500, relative to the expected transcription start site (+1),which was consequently
utilized to determine the methylation status of the SFRP2 promoter (Figure 1a).
We aimed to evaluate the SFRP2 methylation status in both CRC tissue and adjacent tumor-free
tissue from 75 CRC patients, by pyrosequencing after bisulfite treatment.
The results revealed hyper-methylation of the SFRP2 promoter, since SFRP2 methylation in tumor
tissue was significantly higher (40.30%)in comparison to the levels obtained for adjacent tumor-free
tissue areas (17.86%). Conversely, LINE-1 methylation was significantly decreased in the tumor area
(57.38%), when compared to the tumor-free area (63.50%) (Figure 1b).
In addition, to test whether the hyper-methylation of SFRP2 promoter is functionally associated
with a down-regulated expression of SFRP2 at the transcriptomic level, we performed in vitro
demethylation assays, using different colorectal carcinoma cell lines.
Accordingly, we employed RT-qPCR assays to evaluate whether SFRP2 mRNA is differentially
expressed, before and after treatment, with a methylation inhibitor. First, we treated cell lines for 72 h
with 5 µM of AZA, a methylation inhibitor. Consequently, we quantified the mRNA expression of
SFRP2 through RT-qPCR. The HTC116 control showed undetectable mRNA expression of SFRP2, while
the HCT116 treated with AZA resulted in a significant and clear increase of mRNA SFRP2 expression,
as shown in Figure 1c. However, despite measuring the SFRP2 gene expression in three different
human colorectal carcinoma cell lines (HCT116, LoVo, and Caco-2), we only observed expression
recovery of SFRP2 in HCT116, after the AZA treatment. The lack of results from the other cell lines
could be explained by their inherent biological heterogeneity from these cell lines.
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picture of the genomic structure of the human SFRP2 gene on chromosome 4q31 and the CpG island
included in this study. Bioinformatic analysis demonstrated seven CpG-rich islands located at the
−1500 position, relating to the transcription start site (+1). (b) Methylation levels of the SFRP2 and
LINE-1 genes in 75 tumor tissue biopsies of CRC and adjacent tumor-free areas were analyzed by
bisulfite treatment and pyrosequencing. C mparison through paired t-test (c) Quantitative RT-PCR
was us d to determi e the expressio of SFRP2 in HTC116, after treatment with AZA, during 72 h.
The mRNA expr ssio of SFRP2 was normalized to the PPIA expr ssion. The results are displayed as
mRNA relative mean expre sion ± D. Abbreviations: SFRP2—secreted frizzled-related prot in type 2;
LINE-1—long interspersed ele ent ty e 1; PPIA—peptidylprolyl I omerase A; HTC116—Homo sapiens
colon colorectal carcinoma; AZA—5-aza-2′- eoxycytidine; ND—not detected.
3.3. Baseline Characteristics of Colorectal Cancer Patients with Regards to their BMI Category
Clinical, pathological, and tumor molecular features according to the BMI in proximal colon
cancer (cecum, ascending col n, and tra sverse colon), distal colon cancer (descending colon, and
sigmoid colon), and rectal colon cancer are summarized in Table 2.
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by chi-square test.
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Abbreviations: BMI—Body mass index; CRC—colorectal cancer.
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We observed that there were no differences between the two groups for any of the oncological
variables studied.
3.4. Methylation of SFRP2 in CRC Tissue is Associated with BMI
In order to investigate whether adiposity affects DNA methylation levels, the methylation
pattern of SFRP2 and LINE-1 was compared in tumor tissue and tumor-free area, in both BMI groups.
Our results showed that the SFRP2 methylation was significantly lower in overweight/obese individuals
(34.06%), compared to the non-obese individuals (51.24%) (Figure 2a), while LINE-1 methylation did
not show any significant difference in BMI (56.68% for non-obese subjects and for overweight/obese
individuals 57.69%) (Figure 2b). We also observed a significant negative correlation between global
LINE-1 and SFRP2 methylation in CRC tumor tissue (r = −0.329, p = 0.011) (Figure 2c). However, when
the subjects were divided according to the BMI, this association only remained significant in subjects
with BMI < 25 (Figure 2d,e).
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Figure 2. Relationship between BMI and SFRP2 methylation in colorectal cancer. Methylation levels of
the SFRP2 (a) and LINE-1 (b) genes, in 75 tumor tissue biopsies of CRC and adjacent tumor-free areas,
in BMI < 25 and BMI > 25 kg/m2, analyzed by Mann–Whitney U-test. (c) Correlations between global
methylation in SFRP2 and LINE-1 genes in all subjects (d) in individuals with BMI < 25 kg/m2 and (e)
those with BMI > 25 kg/m2 subjects. Abbreviations: SFRP2—Secreted frizzled-related protein type 2;
LINE-1—Long interspersed element type 1; BMI—body mass index.
3.5. SFRP2Methylation in CRC Patients with and without Neoadjuvant Treatment
The specific location of the tumor is a factor to be considered, as they could present biological
and clinical differences. We analyzed the methylation SFRP2 status according to the tumor location.
First of all, we observed that SFRP2 methylation was significantly higher n the right-sided CRC
(57.33%), as compar d to the left-si ed CRC (36.60%). However, in this classification, most patient
tumor s mpl s were derived from the r ctum.
Primary rect l cancer r quire specific surgical treatment (total me orectal exc sion, preceded by
neoadjuvant radiotherapy or chemoradiotherapy); so we aimed to evaluate whether the neoadjuvant
therapy could be affecting the methylation levels. Patients who received treatment displayed lower
SFRP2 methylation levels than those without treatment, within the tumor tissue, though not in the
tumor-free area (Figure 3a). Finally, we assessed the SFRP2 methylation status according to the BMI,
in the treated and the non-treated patients. In the group of patients who received neoadjuvant therapy,
there was no statistical difference in the SFRP2 methylation levels regarding BMI. However, within the
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non-treated patients, those with BMI > 25 showed significantly lower SFRP2 methylation levels, when
compared to the BMI < 25 group (Figure 3b), albeit only in the tumor samples.
At last, to evaluate whether this association between SFRP2 methylation and therapy could be
due to other potential confounder variables, we performed a multivariable analysis, including age,
BMI and presence of diabetes mellitus. We proved that neoadjuvant treatment was the main variable
explaining the variability of SFRP2 methylation levels (Table 3).
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Figure 3. Analysis of abdominal location and therapy of CRC on the SRFP2 methylation. Analysis of
location and CRC patients treated on SFRP2 methylation status. Methylation levels of the SFRP2 divided
by the treated versus the non-treated patients in areas with tumor and in tumor-free areas (a), and rectum
separated by BMI in the treated versus the non-treated patients only in the samples with tumors
(b). Mann-Whitney U-test was performed to compare the means. Abbreviations: SFRP2—Secreted
frizzled-related protein type 2; BMI—body mass index.
Table 3. Multivariate regression analysis of SFRP2 methylation levels according to the neoadjuvant therapy.
R2 = 0.280 95% IC
Variables Standardized β p Value Lower Bound Upper Bound
BMI
(BMI < 25 vs. BMI > 25) −0.339 0.022 −32.166 −2.700
Neoadjuvant therapy
(treated vs. non treated) −0.419 <0.001 −33.657 −5.860
Diabetes mellitus
(diabetic vs. no diabetic) −0.297 0.064 −34.535 1.013
Ag (years) 0.188 0.218 −0.284 1.201
4. Discussion
Aberrant DNA methylation in gene promoters has been strongly associated with key
dysregulations in the oncogenesis for most human tumor models, including colorectal cancer [29].
Presently, there is a large list of established genes subjected to abnormal DNA methylation that are
consequently implicated in pivotal physiological processes, including tumor suppression, hich can
ultimately prove to be of essential utility as novel, epigenetics-based tumor biomarkers [30].
In this study, we evaluated the methylation status of SFRP2, which functionally acts as an
inhibitor of Wnt signaling in CRC, together with BMI influences on such a methylation status. CRC is
most commonly initiated by accumulation of β catenin in the Wnt signaling pathway, leading to the
activation of the Wnt target genes [31].
However, contradicting results were also published in the scientific literature, stating that the
modification of the prognostic impact of obesity by a positive status for nuclear β catenin was associated
with a significantly improved survival rate for colorectal cancer [32].
The results of our study demonstrated that decreased SFRP2 methylation in CRC was associated
with an increased BMI. It has been established that adipose tissue is associated with local inflammation
due to increased production of cytokines and pro-inflammatory factors through the macrophages
present in adipose tissue [33]. This inflamed state was able to create a chronic low-grade inflammation
that can activate the Wnt/β catenin pathway, where SFRP2 plays an important regulatory role in the
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carcinogenesis process of CRC [34]. In essence, the functional role of SFRP2 in CRC and its potential
influence through an increased BMI, could explain, at least partially, the process through which
obesity and Wnt/β catenin might exert their effect on carcinogenesis through independent molecular
pathways [35].
The SFRP2 methylation status was found to be associated with a decreased gene expression of
SFRP2 [36] and, furthermore, was found to be involved in carcinogenesis through down-regulation of
tumor suppressor genes. Indeed, SFRP2 can be detected in many biological samples, such as serum and
stools, rendering it a potential non-invasive biomarker for many carcinogenic processes [37]. In this
study we discovered that SFRP2 was hypermethylated in CRC tumor tissue, when compared to adjacent
tumor-free tissue areas. In addition, the hypermethylated SFRP2 in vitro (as found in the HTC116
CRC tumoral cell line) were presumably associated with suppression of gene expression. Following
treatment with AZA as a demethylating agent, the expression of SFRP2 was significantly increased and
restored. This suggests that SFRP2 demethylation has a functional role in the transcriptional control of
SFRP2. Our study was not focused on exploring the potential mechanisms involved in this decrease of
DNA methylation pattern, although a possible explanation could be due to a de-regulation of DNA
methyltransferase 1 (DNMT1). In most tumors, an altered regulation of this enzyme was described,
which is involved in maintaining methylation patterns [38]. Studies have shown that DNMT inhibition
promotes gene expression of SFRP2, suggesting DNMTs can modulate SFRP2 methylation status [39].
Genome-wide DNA hypo-methylation of LINE-1 is associated with a worse prognosis in early-stage
colorectal cancer, though the majority of the performed studies did not reveal a relation between LINE-1
hypomethylation and clinical outcome in more advanced disease stages [40]. However, our study
results confirmed this association, since we revealed a low methylation rate for LINE-1 in tumor samples,
without any association or relationship with the clinical–pathological parameters of colorectal tumors.
Previous studies have reported that the location of tumors could influence treatment choice,
whereby a large percentage of survival patients were specifically patients who presented primary CRC
tumors on the left-side of the abdomen [41]. Consequently, we focused our study on SFRP2 methylation
in rectum tumor samples. Treated patients demonstrated a decrease of SFRP2 methylation, independent
of the BMI value. This supports the hypothesis that both SFRP2 methylation and BMI could have a
potential role in the development of CRC. Additionally, in the non-treated group, we observed higher
SFRP2 methylation levels in patients with low BMI, suggesting a possible tumor suppressor role of
SFRP2 in overweight/obese patients.
These results point to a possible interaction between BMI and neoadjuvant treatment. Moreover,
recently, described epigenetic changes in DNA have also been underlined as mediators of the networking
between obesity and cancer [42,43]. Li et al. reported that obesity led to epigenetic remodeling that
resulted in differential gene expression related to metabolism and tumorigenesis. Moreover, this
epigenetic signature could be reverted by weight loss reinforcing the role of BMI in the epigenetic mark
of genes involved in neoplasia [44].
Limitations of this research include the lack of large cohort groups in order to analyze the effect of
therapy with more statistical significance and perform survival studies. We could also not demonstrate
the causal relation between methylation and gene expression, since expression data were obtained from
human colon cancer cell lines. Finally, due to the challenge involved in obtaining high integrity RNA
from tumor paraffin-embedded samples, we could not evaluate the gene expression from different
DNA methyltransferases.
5. Conclusions
We demonstrated that the DNA methylation levels of SFRP2 are lower in overweight/obese
patients, in comparison with non-obese patients, specifically in tumor areas, supporting the hypothesis
that BMI could play a protective role in the development of CRC. We also examined that the patients
undergoing neoadjuvant treatment showed similar methylation values of SFRP2, independent of their
BMI, suggesting that neoadjuvant treatment might have an effect on the epigenetic regulation of SFRP2,
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though further studies of clinical pathologies for such patients would be necessary to strengthen these
preliminary results.
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